Pinealon
Distribution of the patients by nosological groups, sex and age. Table 1
Diagnosis Age Men Women Total
(years)
Control group Main Control group Main Control group Main
group group group
Long-term effects of 35-65 5 7 1 1 6 8
craniocerebral injury
State after stroke 56-75 5 6 1 3 6 9
Vascular 55-78 5 7 5 8 10 15
encephalopathies
Signs of decreased 51-68 6 5 4 5 10 10
mental capacity,
memory, attention.
Total: 21 25 11 17 32 42
RESEARCH METHODS
The effectiveness of PINEALON® was assessed by the dynamics of subjective indicators and objec-
tively using the methods of proofreading and electroencephalography (EEG).
RESEARCH RESULTS
After administrating PINEALON® to patients of the primary group, a good clinical result was observed
in 66.7% of cases, satisfactory - in 23.8%, no positive effect - in 9.5% of cases (in the control group -
Table 2). There was no negative effect of PINEALON® on the condition of the patients.
PINEALON® efficiency in patients with diseases of the central
nervous system Table 2
Treatment results Group of patients
Treatment using general purpose medication Treatment using “Pinealon”
Abs. % Abs. %
Good 9 28,1 28 66,7*
Satisfactory 13 40,6 10 23,8
Not satisfactory 10 31,2 4 9,5*
Total: 32 100 42 100
* Р<0,05 in comparison with the parameters after treatment using general purpose drugs.
When comparing the subjective indicators of the state of patients before and after the use of PINE-
ALON®, it was found that the number of health complaints decreased by 2-3 times. Patients noted
an improvement in memory, intelligence, a decrease in the intensity and duration of headaches, the
appearance of emotional balance, volitional qualities, and a sense of rest after a night’s sleep (Table 3).
Patients with the consequences of craniocerebral injury and stroke noticed a moderate regression
of focal symptoms, improved speech function with motor and sensory aphasia, and decreased mus-
cle spasticity.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.